Biogen Inc.는 미국, 유럽, 독일, 아시아 및 전 세계에서 치료제를 발굴, 개발, 제조 및 공급합니다. 이 회사는 다발성 경화증 치료제인 TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI와 척수성 근위축증 치료제 SPINRAZA, 프리드리히 운동실조증 치료제 SKYCLARYS, 근위축성 측삭 경화증 치료제 QALSODY 등을 제공합니다. 또한 플라크 건선 치료제 FUMADERM과 ENBREL 바이오시밀러 BENEPALI, HUMIRA 바이오시밀러 IMRALDI, REMICADE 바이오시밀러 FLIXABI를 공급합니다.
이 회사는 알츠하이머병 치료제 LEQEMBI, 산후 우울증 치료제 ZURZUVAE, 비호지킨 림프종 및 만성 림프구성 백혈병 치료제 RITUXAN 등을 제공합니다. Biogen Inc.는 Merz Therapeutics, Alkermes Pharma Ireland Limited, Eisai Co., Ltd., Genentech, Inc., Samsung Bioepis 등과 협력 및 라이선스 계약을 맺고 있습니다. 또한 Dravet 증후군 치료제 zorevunersen 개발을 위해 Stoke Therapeutics, Inc.와 협력하고 있습니다.
영어 원문 보기
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
